The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation.
OBJECTIVE
2-arachidonoylglycerol (2-AG) is an endocannabinoid whose hydrolysis is predominantly catalysed by the enzyme monoacylglycerol lipase (MAGL). The development of MAGL inhibitors could offer an opportunity to investigate the anti-inflammatory and anti-nociceptive role of 2-AG, which have not yet been elucidated. On these bases, URB602, a MAGL inhibitor, was tested in a murine model of inflammation/inflammatory pain.


METHODS
Acute inflammation was induced by intraplantar injection of lambda-carrageenan into mice. The highest dose to be employed has been selected performing the tetrad assays for cannabimimetic activity in mice. URB602 anti-inflammatory and anti-nociceptive efficacy (assessed by plethysmometer and plantar test, respectively) was evaluated both in a preventive regimen (drug administered 30 min before carrageenan) and in a therapeutic regimen (URB602 administered 30 min after carrageenan). To elucidate the cannabinoid receptor involvement, rimonabant and SR144528, CB1 and CB2 selective antagonists, respectively, were given 15 min before URB602.


RESULTS
Systemic administration of URB602 elicited a dose-dependent anti-oedemigen and anti-nociceptive effect that was reversed exclusively by the CB2 receptor antagonist. The efficacy of URB602 persisted also when the compound was administered in a therapeutic regimen, suggesting the ability of URB602 to improve established disease.


CONCLUSIONS
The present report highlighted the ability of the selective MAGL inhibitor, URB602, to prevent and treat an acute inflammatory disease without producing adverse psychoactive effects. The data presented herein also contributed to clarify the physiological role of 2-AG in respect to inflammatory reactions, suggesting its protective role in the body.
Comelli
F
F
Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milano, Italy.
Giagnoni
G
G
Bettoni
I
I
Colleoni
M
M
Costa
B
B
D000208:Acute Disease; D000818:Animals; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D001892:Camphanes / Q000494:pharmacology; D002351:Carrageenan / Q000008:administration & dosage / Q000633:toxicity; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D006614:Hindlimb; D006930:Hyperalgesia / Q000139:chemically induced / Q000517:prevention & control; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008994:Monoacylglycerol Lipases / Q000037:antagonists & inhibitors*; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D010147:Pain Measurement / Q000379:methods; D017288:Pain Threshold / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors; D000077285:Rimonabant
D001713:Biphenyl Compounds; D001892:Camphanes; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C110630:SR 144528; C501835:URB602; D002351:Carrageenan; D008994:Monoacylglycerol Lipases; D000077285:Rimonabant
Glia. 2003 Jan 15;41(2):161-8
12509806
Chem Phys Lipids. 2002 Dec 31;121(1-2):149-58
12505697
Br J Pharmacol. 1972 Dec;46(4):753-63
4655271
Pain. 1983 Jun;16(2):109-10
6877845
Pain. 1988 Jan;32(1):77-88
3340425
Science. 1992 Dec 18;258(5090):1946-9
1470919
J Pharmacol Exp Ther. 1993 Apr;265(1):218-26
8474008
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
7605349
Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97
7575630
Nature. 1997 Aug 21;388(6644):773-8
9285589
J Pharmacol Exp Ther. 1998 Feb;284(2):644-50
9454810
Biochem J. 1998 Apr 1;331 ( Pt 1):15-9
9512456
Mol Pharmacol. 1998 Apr;53(4):676-83
9547358
J Biol Chem. 1999 Jan 29;274(5):2794-801
9915812
J Biol Chem. 2005 May 6;280(18):18488-97
15749716
Pharmacol Biochem Behav. 2005 Jun;81(2):224-38
15935454
Nature. 2005 Jun 23;435(7045):1108-12
15973410
Nat Neurosci. 2005 Sep;8(9):1139-41
16116451
Behav Pharmacol. 2005 Sep;16(5-6):363-72
16148440
Br J Pharmacol. 2005 Oct;146(3):467-76
16100529
Neuropharmacology. 2006 Mar;50(3):372-9
16316669
Eur J Pharmacol. 2006 May 24;538(1-3):154-62
16647054
J Neurosci. 2007 Mar 14;27(11):2883-9
17360910
Br J Pharmacol. 2007 Mar;150(6):693-701
17179944
Eur J Pharmacol. 2007 Aug 13;569(1-2):70-6
17553486
Eur J Pharmacol. 1999 Nov 19;384(2-3):153-6
10611435
J Biol Chem. 2000 Jan 7;275(1):605-12
10617657
Mol Pharmacol. 2000 May;57(5):1045-50
10779390
Eur J Pharmacol. 2000 Oct 6;406(1):R5-7
11011050
Br J Pharmacol. 2001 Oct;134(3):664-72
11588122
Eur J Pharmacol. 2001 Nov 30;432(1):107-19
11734194
J Biol Chem. 2002 Jan 18;277(3):1816-23
11682480
Pharmacol Biochem Behav. 2002 Nov;73(4):911-9
12213538
Mol Pharmacol. 2004 Nov;66(5):1260-4
15272052